Clinical Trial: A multicenter, prospective study of adebrelimab in combination with apatinib and the AG regimen as first‑line therapy for PD‑L1‑positive locally advanced or metastatic pancreatic cancer (China)

China, Aug. 14 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A multicenter, prospective study of adebrelimab in combination with apatinib and the AG regimen as first‑line therapy for PD‑L1‑positive locally advanced or metastatic pancreatic cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130046

Registration Time: 2026/08/13

Type: Interventional study

Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337639

Published by HT Digital Content Services with permission from Health Daily Digest....